share_log

Genix Announces AGM Results

Genix Announces AGM Results

Genix 公佈股東周年大會業績
newsfile ·  2023/05/26 16:27

Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") is pleased to report the results of the Annual General Meeting of shareholders held on May 18, 2023 (the "AGM"). Each of the director nominees proposed by management for election were elected to the Board of Directors: Sina Pirooz, Mahmoud Aziz, Kevin Bottomley, Jamie Lewin, and Paul Chow.

溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年5月26日)-Genix製藥公司(多倫多證券交易所股票代碼:GEnx)(場外交易市場代碼:GENPF)(“Genix”或“公司”)高興地報告於2023年5月18日舉行的股東周年大會的結果(“年度股東大會管理層提名的每一位董事候選人都當選為董事會成員:新浪皮魯茲、馬哈茂德·阿齊茲、凱文·博託姆利、傑米·萊文和周保羅。

In addition, the following resolutions presented below were also voted overwhelmingly in favour by shareholders at the AGM.

此外,股東於股東周年大會上亦以壓倒性多數投票贊成下列決議案。

  • Setting the number of directors for the ensuing year at five (5);
  • Re-appointment of Buckley Dodds CPA, Chartered Professional Accountants, as auditor of the Company for the coming year and authorizing the directors to determine the auditor's remuneration;
  • Re-approval of the Company's Stock Option Plan for the following year; and
  • Re-pricing of Certain existing Options
  • 將下一年度的董事人數定為五(5)人;
  • 重新委任註冊會計師巴克利·道茲為本公司來年的核數師,並授權董事釐定核數師的酬金;
  • 重新批准公司下一年度的股票期權計劃;以及
  • 某些現有期權的重新定價

The Company would like to express its gratitude to Mr. Darryl Yea for his invaluable support and contributions acting as the Chairman of the board since 2020. We extend our sincerest thanks and best wishes to him for all his future endeavors.

本公司謹向葉達理先生致謝,感謝他自2020年起擔任董事會主席以來對本公司的寶貴支持和貢獻。我們向他致以最誠摯的感謝和最良好的祝願,祝願他今後的一切努力。

The Board of Directors has elected Mr. Mahmoud Aziz to act as the Company's Chairman of the Board and will continue his role as President of Genix.

董事會已選舉馬哈茂德·阿齊茲先生為公司董事會主席,並將繼續擔任Genix的總裁。

Genix would like to thank all the shareholders for their participation and continued support.

Genix感謝所有股東的參與和持續支持。

About Genix

關於Genix

Genix Pharmaceuticals Corporation is a novel nutraceutical and generic ophthalmic drugs company that is focused on the research, development, manufacture, licencing, and sales of innovative healthcare products.

Genix製藥公司是一家新型的營養食品和仿製藥眼科藥物公司,專注於創新保健產品的研究、開發、製造、許可和銷售。

In particular, these products include evidence-based, proprietary over-the-counter ("OTC") nutraceuticals, and other single molecule generic drugs that have been shown to deliver consistent and verifiable results in various therapeutic areas.

特別是,這些產品包括循證的、專有的非處方藥(“OTC”)營養食品,以及其他單分子仿製藥,已被證明在不同的治療領域提供一致和可驗證的結果。

At Genix, we understand the importance of scientific advancement and continuously strive to develop new and innovative products. Our team remains committed to addressing the health needs of consumers and supporting their well-being.

在Genix,我們理解科學進步的重要性,並不斷努力開發新的和創新的產品。我們的團隊繼續致力於滿足消費者的健康需求,並支持他們的福祉。

On Behalf of the Board of Directors,
"Mahmoud Aziz"

我謹代表董事會:
《馬哈茂德·阿齊茲》

Mr. Mahmoud Aziz
President, Chairman of the Board
Genix Pharmaceuticals Corporation

馬哈茂德·阿齊茲先生
總裁,董事會主席
Genix製藥公司

For more information regarding Genix Pharmaceuticals Corporation, please contact:

欲瞭解有關Genix製藥公司的更多資訊,請聯繫:

Kevin Bottomley, Director
Tel: +1.604.609.6199
kbottomley@genixpharm.com

凱文·博託姆利,董事
電話:+1.604.609.6199
郵箱:kbottomley@genixPharm.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任

Cautionary Note Regarding Forward-Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as "continue", "efforts", "expect", "believe", "anticipate", "confident", "intend", "strategy", "plan", "will", "estimate", "project", "goal", "target", "prospects", "optimistic" or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company's ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

有關前瞻性陳述的注意事項:本新聞稿含有涉及風險和不確定因素的前瞻性陳述。這些陳述可能與未來的實際事件或結果大相徑庭,並基於當前的預期或信念。為此目的,有關歷史事實的陳述可被視為前瞻性陳述。此外,前瞻性陳述還包括公司使用諸如“繼續”、“努力”、“期望”、“相信”、“預期”、“自信”、“打算”、“戰略”、“計劃”、“將”、“估計”、“專案”、“目標”、“目標”、“前景”、“樂觀”或類似表述的陳述。這些陳述的性質涉及風險和不確定因素,實際結果可能會因各種重要因素而大不相同,這些因素包括但不限於公司及時和完全提供足夠的當前公共資訊的能力和持續努力、可能施加的額外或不同的監管和法律要求和限制,以及公司提交給SEDAR的檔案中可能討論的其他因素(),包括確定可能導致實際結果與前瞻性陳述所載結果不同的重要風險因素的最新報告。公司不承擔任何義務來審查或確認分析師的預期或估計,或公開發布對任何前瞻性陳述的任何修訂,以反映此後發生的事件或情況,或反映意外事件的發生。投資者不應過度依賴前瞻性陳述。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論